Taconic Biosciences

Adroit DI Appoints Experienced Industry Leader to drive Expansion in North America

Retrieved on: 
Tuesday, October 17, 2023
Data Management, Technology, Other Science, Networks, Research, Science, Internet, Taconic Biosciences, Organization, Carestream Health, Caliper Life Sciences, Data management, Pharmaceutical industry, Management

“I am thrilled to announce the appointment of John S. DelliSanti as President of North America and Chief Commercial Officer for Adroit DI.

Key Points: 
  • “I am thrilled to announce the appointment of John S. DelliSanti as President of North America and Chief Commercial Officer for Adroit DI.
  • His leadership has consistently delivered results by nurturing strong customer relationships and employee engagement,” said Richard Lingard, CEO Adroit DI.
  • John S. DelliSanti, President of North America and Chief Commercial Officer for Adroit DI, said, "I'm honored to join Adroit DI and lead the expansion of their innovative data management solutions across North America.
  • I look forward to partnering with Richard and the talented Adroit DI team as we help more organizations accelerate their important research."

H.I.G. Capital Completes Acquisition of Celerion

Retrieved on: 
Thursday, November 3, 2022
Banking, Research, General Health, Professional Services, Pharmaceutical, Other Manufacturing, Clinical Trials, Science, Biotechnology, Finance, Health, Other Science, Manufacturing, Company, Growth, Investment, Biotechnology, Whitehorse, CLO, Industry, BDC, Data management, Paulo, Cros, Organization, Winston & Strawn, Clinical trial, Taconic Biosciences, McDermott Will & Emery, Drug development, Rothschild, Acquisition, H.I.G. Capital, United Kingdom, Financial services, Fine chemical, Pharmaceutical industry, Michael Leiter

), a leading global investment firm with $52 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Celerion Holdings, Inc. (Celerion or the Company), a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.

Key Points: 
  • ), a leading global investment firm with $52 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Celerion Holdings, Inc. (Celerion or the Company), a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.
  • Celerion has locations in the United States, Canada, Austria, South Korea, Switzerland, and the United Kingdom.
  • Susan Thornton, Ph.D., Chief Executive Officer of Celerion commented, We are excited to enter into this new chapter of growth with H.I.G.
  • We believe Celerion is well-positioned for continued growth, given its dedication to the most rigorous quality and performance standards.

H.I.G. Capital Completes Sale of Taconic Biosciences

Retrieved on: 
Tuesday, November 1, 2022
Research, Finance, Professional Services, Biotechnology, Health, Pharmaceutical, Other Science, Other Professional Services, Science, Whitehorse, BDC, Growth, Taconic Biosciences, Perella Weinberg Partners, Avista Capital Partners, CRO, Partnership, H.I.G. Capital, Research, Gemstone, CLO, Sale, Investment, Company, Neurology, Association, Biotechnology, Financial services, Fine chemical, Risk management, Taconic

), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (Taconic or the Company) to Avista Capital Partners (Avista).

Key Points: 
  • ), a leading global alternative investment firm with $52 billion of equity capital under management, is pleased to announce the sale of its portfolio company Taconic Biosciences (Taconic or the Company) to Avista Capital Partners (Avista).
  • The Taconic team benefited from H.I.G.s support and partnership as we worked to achieve our shared growth goals and strategic mission.
  • Taconic has established itself as a market leader and is well positioned for continued growth under its new sponsor Avista.
  • Taconic Biosciences, Inc. is one of the worlds leading suppliers of murine research models for pharmaceutical, biotechnology, CRO, and academic research clients.

Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment

Retrieved on: 
Monday, October 24, 2022
NOG, Therapy, Neoplasm, Autoimmune disease, Animal, Tissue, Taconic Biosciences, Immune system, Drug discovery, FC, GLOBE, Monoclonal antibody, Solution, Fc receptor, Vaccine, Taconic

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcRs) known to confound results in antibody-based therapy studies.

Key Points: 
  • RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcRs) known to confound results in antibody-based therapy studies.
  • Murine FcRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery.
  • Taconics FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.
  • The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse.

Global Rat Model Market Research 2022-2027: Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area - ResearchAndMarkets.com

Retrieved on: 
Friday, July 22, 2022
Health, Other Health, Transfer, SWOT, Investment, Others, COVID-19, Market development, Environmental impact of pharmaceuticals and personal care products, Microinjection, Industry, Genetic testing, Risk, Quarantine, Inflammation, USD, Ansoff Matrix, Geography, CAGR, Clinical trial, Horizon Discovery, Taconic Biosciences, Children's Environmental Exposure Research Study, Neurology, Rat, Emotion, Competitive analysis, Diabetes, Impact, Growth, Pharmaceutical industry, Retail, Risk management, Trapping, Cryopreservation, Cages, Envigo, Technology, CRISPR, Toxicology, Breeding

The "Global Rat Model Market (2022-2027) by Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Rat Model Market (2022-2027) by Clinical Trials & Research, Model Type, Service, Technology, Therapeutic Area, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Market dynamics are forces that impact the prices and behaviors of the Global Rat Model Market stakeholders.
  • The report analyses the Global Rat Model Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • By Clinical Trials & Research, the market is classified into Clinical Trials, and Research Studies.

Taconic Biosciences Appoints Nomura Siam as Distributor in India for All Taconic Animal Models

Retrieved on: 
Tuesday, May 10, 2022
Gemstone, Taconic Biosciences, Immune system, Mouse, GLOBE, Â, Breeding, Biotechnology, NSI, Research, Toxicology, Partnership, Animal, Sesame Street international co-productions, International, Therapy, Solution, Growth, Japan, Pharmaceutical industry, Taconic

RENSSELAER, N.Y., May 10, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.

Key Points: 
  • RENSSELAER, N.Y., May 10, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.
  • To support this growth, scientists in India need advanced mouse and rat models for pharmacology studies and toxicology and drug safety assessment.
  • Taconics portfolio comprises nearly 4,700 mouse and rat models, including widely used standard strains, immunodeficient models, and exclusive GEMs.
  • Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide.

Taconic Biosciences and Biomodels Establish Microbiome Initiative

Retrieved on: 
Tuesday, April 26, 2022
Systems biology, Fibrosis, Biotechnology, Microbiota, Microbiology, Research, GLOBE, Â, RATS, Research design, Solution, CRO, Degenerative disease, Industry, Disease, Taconic Biosciences, Health, Pharmaceutical industry, Antibiotics, Taconic

RENSSELAER, N.Y., April 26, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels , a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI) , providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.

Key Points: 
  • RENSSELAER, N.Y., April 26, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels , a provider of contract research services for preclinical drug development, have launched the Taconic-Biomodels Microbiome Initiative (TBMI) , providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data.
  • Yet, the field of microbiome research has been hampered by a lack of seamless access to the essential foundational capabilities these studies require.
  • Together, Taconic and Biomodels are bridging the most significant gap in microbiome researchenabling more investigators to participate in this transformative field and make data-informed decisions with great confidence, said Dr. John Couse, vice president, scientific services, Taconic.
  • Biomodels and Taconic share the view that a successful microbiome study requires an integrated experience, from study design and model selection to accurate data, which is what our initiative delivers, said Dr. Greg Lyng, chief operating officer, Biomodels.

Taconic Biosciences Improves rasH2 Carcinogenicity Test System Access in Asia-Pacific Region

Retrieved on: 
Monday, March 21, 2022
Taconic Biosciences, Adoption, Human, Central Institute for Experimental Animals, Russell, European Medicines Agency, Diet, Sesame Street international co-productions, Animal, Research, Environment, CEO, Health, Food, 3R, US Foods, International, Tg-rasH2 mouse, GLOBE, EMA, Drug discovery, Solution, NSI, CLEA, FDA, Partnership, Pharmaceutical industry, Fine chemical, Taconic

Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively.

Key Points: 
  • Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively.
  • These distribution arrangements greatly improve rasH2 access for the burgeoning pharmaceutical industry in the Asia-Pacific region.
  • The rasH2 transgenic mouse model is the only short-term (6-month) carcinogenicity test system that is both accepted by global regulatory authorities and readily available in commercial production.
  • "This historic collaboration ensures customers in every country have full access to the rasH2 carcinogenicity test system, said Ryuta Nomura, CIEA chairman of the board and CEO.

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Retrieved on: 
Thursday, March 3, 2022
Private Securities Litigation Reform Act, Synthetic biology, Phenylketonuria, Information, HCU, PKU, Research, CFO, Financial management, Lists of diseases, Roche, Homocystinuria, Inflammatory bowel disease, Metabolism, Towson University, SEC, Copenhagen Business School, Probiotic, Business administration, Clinical trial, Intrinsic and extrinsic properties, Risk, Taconic Biosciences, Bachelor of Business Administration, Novartis, Genetic engineering, GLOBE, Therapy, Pharmaceutical industry, Economics, AbbVie, MD

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc.(Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer.

Key Points: 
  • CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc.(Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer.
  • Mr. Jensen brings extensive and diversified experience within global pharmaceutical and medical device companies to Synlogic, spanning analytics, financial management, information systems, and operations.
  • Ch.B., Synlogic President and Chief Executive Officer.
  • Michael has an impressive finance and operations background from his roles at multiple biopharma and healthcare companies.

Taconic Biosciences® Launches Cage+™, Redefining Colony Management Solutions for the Modern Laboratory

Retrieved on: 
Monday, February 21, 2022
Taconic Biosciences, GLOBE, Breeding, Pharmacy, Industry, Solution, Research, Communication, Biomedicine, Time, Agriculture, Taconic

Studies are more advanced and rapid-paced, compressing the time to produce experimental data required to support well-informed decisions.

Key Points: 
  • Studies are more advanced and rapid-paced, compressing the time to produce experimental data required to support well-informed decisions.
  • Taconics Cage+ Colony Management Solutions closes the gap between biomedical research program demands and the antiquated approach offered by many contract breeding services.
  • When coupled with Taconics Custom Model Generation Solutions , Cage+ Colony Management Solutions brings a comprehensive and seamless design to management service, allowing clients to leverage the most complex genetically engineered models from initial design through to scaled production of study cohorts.
  • Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide.